Pharmacokinetic Propertiese of Entecavir 1 mg in Korean Healthy Volunteers
![]() |
Jeon, Ji-Young
(Clinical Trial Center, Chonbuk National University Hospital)
Hwang, Min-Ho (Clinical Trial Center, Chonbuk National University Hospital) Im, Yong-Jin (Clinical Trial Center, Chonbuk National University Hospital) Kim, Yun-Jeong (Clinical Trial Center, Chonbuk National University Hospital) Han, Su-Mi (Clinical Trial Center, Chonbuk National University Hospital) Im, Sung-Hyuk (Seoul Pharma Laboratories) Chae, Soo-Wan (Clinical Trial Center, Chonbuk National University Hospital) Kim, Min-Gul (Clinical Trial Center, Chonbuk National University Hospital) |
1 | Shepard CW, Simard EP, Finelli L, et al., Hepatitis B virus infection: epidemiology and vaccination. Epidemiol Rev 28:112-25, 2006. DOI ScienceOn |
2 | Innaimo SF, Seifer M, Bisacchi GS, et al: Identification of BMS-200475 as a potent and selective inhibitor of hepatitis B virus. Antimicrob Agents Chemother 41: 1444-8, 1997. |
3 | Chang TT, Gish RG, de Man R, et al., A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 354: 1001-10, 2006. DOI ScienceOn |
4 | Lai CL, Shouval D, Lok AS, et al., Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 354: 1011-20, 2006. DOI ScienceOn |
5 | Lampertico P: Entecavir versus lamivudine for HBeAg positive and negative chronic hepatitis B. J Hepatol 45: 457-60, 2006. DOI ScienceOn |
6 | Rivkin A: A review of entecavir in the treatment of chronic hepatitis B infection. Curr Med Res Opin 21:1845- 56, 2005. DOI ScienceOn |
7 | Cho SW: Chronic Hepatitis B. 대한간학회지 16권:12-19, 2010. |
8 | Yan JH, Bifano M, Olsen S, et al., Entecavir pharmacokinetics, safety, and tolerability after multiple ascending doses in healthy subjects. J Clin Pharmacol 46: 1250-8, 2006. DOI ScienceOn |
9 | Highlight of prescribing information: BARACLUDE (entecavir) Tablets, Bristol-Myers Squibb Company, Initial U.S. Approval: 2005. |
10 | Adopted by the 18th WMA General Assembly H, Finland, June 1964, and amended by the 59th WMA General Assembly, Seoul: WORLD MEDICAL ASSOCIATION DECLARATION OF HELSINKI Ethical Principles for Medical Research Involving Human Subjects., 2008. |
11 | 의약품 임상시험 관리기준. 식품의약품안전청 고시 제 2009-211호. |
![]() |